Literature DB >> 8556510

Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

H B Slade1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556510      PMCID: PMC368373          DOI: 10.1128/cdli.1.6.613-619.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


× No keyword cloud information.
  74 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus.

Authors:  A M Prince; B Brotman; G F Grady; W J Kuhns; C Hazzi; R W Levine; S J Millian
Journal:  Lancet       Date:  1974-08-03       Impact factor: 79.321

3.  Transmission of hepatitis after the administration of intravenous immunoglobulins.

Authors:  R H Rousell; M B Dobkin; M D Budinger; R E Louie
Journal:  Am J Clin Pathol       Date:  1993-05       Impact factor: 2.493

4.  Testing for HCV-RNA in commercial intravenous immunoglobulins.

Authors:  J J Lefrère; M Mariotti; C Trepo; J S Li; F Lunel; L Frangeul; F Letourneur; J P Laporte; A M Jullien
Journal:  Lancet       Date:  1993-03-27       Impact factor: 79.321

5.  Letter: Acute hepatitis B after administration of gammaglobulin.

Authors:  S Nakamura; T Sato
Journal:  Lancet       Date:  1976-02-28       Impact factor: 79.321

6.  Detection of hepatitis C viral RNA in sporadic acute non-A, non-B hepatitis by polymerase chain reaction. Its usefulness for the early diagnosis of seronegative infection.

Authors:  N Sakamoto; C Sato; H Haritani; S Maekawa; M Kurosaki; N Enomoto; Y Hoshino; J Tazawa; M Nishimura; F Marumo
Journal:  J Hepatol       Date:  1993-01       Impact factor: 25.083

Review 7.  A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study.

Authors:  L B Seeff; H J Zimmerman; E C Wright; J D Finkelstein; P Garcia-Pont; H B Greenlee; A A Dietz; C M Leevy; C H Tamburro; E R Schiff; E M Schimmel; R Zemel; D S Zimmon; R W McCollum
Journal:  Gastroenterology       Date:  1977-01       Impact factor: 22.682

8.  Chronic liver disease due to hepatitis C.

Authors:  S Levi; C Foster; H J Hodgson; K N Ward; A So; J A Garson; J Waxman; D Swirsky
Journal:  BMJ       Date:  1993-04-17

9.  Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection.

Authors:  I Merican; S Sherlock; N McIntyre; G M Dusheiko
Journal:  Q J Med       Date:  1993-02

10.  Failure to detect hepatitis C virus (HCV) genome by polymerase chain reaction in human anti-HCV-positive intravenous immunoglobulins.

Authors:  F Dammacco; D Sansonno; A Beardsley; E J Gowans
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more
  6 in total

Review 1.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

2.  The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.

Authors:  Shun Xin Wang-Lin; Ruth Olson; Janet M Beanan; Ulrike MacDonald; Joseph P Balthasar; Thomas A Russo
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

Review 3.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors:  Jenny Lingman-Framme; Anders Fasth
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 5.  Antibody-based therapies for emerging infectious diseases.

Authors:  A Casadevall
Journal:  Emerg Infect Dis       Date:  1996 Jul-Sep       Impact factor: 6.883

Review 6.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.